Childhood brain stem glioma
disease diseaseOn this page
Also known as brain stem gliomabrain stem glioma of childhoodchildhood brainstem gliomachildhood glioma of brain stemchildhood glioma of brainstemchildhood glioma of the brain stemchildhood glioma of the brainstempaediatric brain stem gliomapaediatric brainstem gliomapaediatric glioma of brain stempaediatric glioma of brainstempaediatric glioma of the brain stempaediatric glioma of the brainstempediatric brain stem gliomapediatric brainstem gliomapediatric glioma of brain stempediatric glioma of brainstempediatric glioma of the brain stempediatric glioma of the brainstem
Summary
Childhood brain stem glioma (MONDO:0003869) is a cancer and 39 clinical trials. Top therapeutic interventions include bevacizumab, lapatinib, and edotreotide gallium ga-68. A subtype of brain stem glioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 39
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | childhood brain stem glioma |
| Mondo ID | MONDO:0003869 |
| DOID | DOID:6383 |
| NCIT | C9042 |
| UMLS | C0278600 |
| MedGen | 124481 |
| GARD | 0009306 |
| Is cancer (heuristic) | yes |
Also known as: brain stem glioma · brain stem glioma of childhood · childhood brain stem glioma · childhood brainstem glioma · childhood glioma of brain stem · childhood glioma of brainstem · childhood glioma of the brain stem · childhood glioma of the brainstem · paediatric brain stem glioma · paediatric brainstem glioma · paediatric glioma of brain stem · paediatric glioma of brainstem · paediatric glioma of the brain stem · paediatric glioma of the brainstem · pediatric brain stem glioma · pediatric brainstem glioma · pediatric glioma of brain stem · pediatric glioma of brainstem · pediatric glioma of the brain stem · pediatric glioma of the brainstem
Disease family
This is a subtype of brain stem glioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › brain cancer › infratentorial cancer › brainstem cancer › brain stem glioma › childhood brain stem glioma
Related subtypes (4): adult brainstem glioma, brain stem astrocytic neoplasm, brain stem ependymoma, brain stem glioblastoma
Subtypes (2): childhood brainstem astrocytoma, diffuse intrinsic pontine glioma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 39.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 22 |
| PHASE2 | 6 |
| Not specified | 4 |
| PHASE3 | 3 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02864888 | PHASE3 | NOT_YET_RECRUITING | Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma |
| NCT02887040 | PHASE3 | NOT_YET_RECRUITING | Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma |
| NCT01236560 | PHASE2/PHASE3 | COMPLETED | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma |
| NCT01635140 | PHASE3 | COMPLETED | Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children |
| NCT00840047 | PHASE2 | ACTIVE_NOT_RECRUITING | Methionine PET/CT Studies In Patients With Cancer |
| NCT00003459 | PHASE2 | COMPLETED | Antineoplaston Therapy in Treating Patients With Brain Stem Glioma |
| NCT00070525 | PHASE2 | COMPLETED | Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma |
| NCT00091182 | PHASE2 | COMPLETED | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment |
| NCT00095940 | PHASE1/PHASE2 | COMPLETED | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors |
| NCT00381797 | PHASE2 | COMPLETED | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma |
| NCT01095094 | PHASE2 | TERMINATED | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma |
| NCT01514201 | PHASE1/PHASE2 | COMPLETED | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas |
| NCT01884740 | PHASE1/PHASE2 | TERMINATED | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 |
| NCT05857969 | PHASE1 | RECRUITING | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling |
| NCT00012181 | PHASE1 | COMPLETED | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas |
| NCT00052780 | PHASE1 | COMPLETED | Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors |
| NCT00053963 | PHASE1 | COMPLETED | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia |
| NCT00063973 | PHASE1 | COMPLETED | Cilengitide in Treating Children With Refractory Primary Brain Tumors |
| NCT00101270 | PHASE1 | COMPLETED | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
| NCT00281944 | PHASE1 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors |
| NCT00326664 | PHASE1 | COMPLETED | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors |
| NCT00363272 | PHASE1 | COMPLETED | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma |
| NCT00576641 | PHASE1 | COMPLETED | Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma |
| NCT00638898 | PHASE1 | COMPLETED | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor |
| NCT00929903 | PHASE1 | COMPLETED | Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment |
| NCT00946335 | PHASE1 | COMPLETED | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors |
| NCT00994500 | PHASE1 | COMPLETED | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma |
| NCT01076530 | PHASE1 | COMPLETED | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors |
| NCT01082926 | PHASE1 | COMPLETED | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 |
| NCT01088763 | PHASE1 | TERMINATED | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia |
| NCT01502917 | PHASE1 | COMPLETED | Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy |
| NCT02255461 | PHASE1 | TERMINATED | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors |
| NCT02415153 | PHASE1 | COMPLETED | Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors |
| NCT03396575 | PHASE1 | TERMINATED | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) |
| NCT04341311 | PHASE1 | TERMINATED | Phase I Study of Marizomib + Panobinostat for Children With DIPG |
| NCT01878266 | Not specified | COMPLETED | Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children |
| NCT02175745 | Not specified | TERMINATED | 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas |
| NCT02194452 | Not specified | WITHDRAWN | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors |
| NCT03860376 | Not specified | COMPLETED | Ex Vivo Drug Sensitivity Testing and Mutation Profiling |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 3 |
| LAPATINIB | 4 | 3 |
| EDOTREOTIDE GALLIUM GA-68 | 4 | 1 |
| FLUDEOXYGLUCOSE F 18 | 4 | 1 |
| FLUORODOPA F 18 | 4 | 1 |
| PALBOCICLIB | 4 | 1 |
| PANOBINOSTAT | 4 | 1 |
| PAZOPANIB HYDROCHLORIDE | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| TEMOZOLOMIDE | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| VELIPARIB | 3 | 4 |
| ALVOCIDIB | 3 | 3 |
| ANTINEOPLASTON A10 | 3 | 2 |
| 6-O-BENZYLGUANINE | 3 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| CILENGITIDE | 3 | 1 |
| MARIZOMIB | 3 | 1 |
| METHIONINE | 3 | 1 |
| TIPIFARNIB | 3 | 1 |
| ISPINESIB | 2 | 1 |
| CHEMBL4228794 | 0 | 1 |
| CHEMBL4248195 | 0 | 1 |
| CHEMBL1234268 | 0 | 1 |
| CHEMBL4066465 | 0 | 1 |
| CHEMBL2326523 | 0 | 1 |
| CHEMBL344227 | 0 | 1 |
| RACEMETHIONINE | -1 | 1 |